Invivyd Q2 Loss Widens to $44M, Misses Estimates on Higher Trial Costs
IVVD sits 38% above its 52-week low of $0.483.
Summary
Invivyd reported a Q2 net loss of $44.39 million, or $0.14 per share, missing consensus estimates of $0.11 per share and $26.98 million net loss. Revenue rose 21% year-over-year to $14.29 million on higher PEMGARDA patient demand, but R&D and SG&A costs surged, driven by the DECLARATION and LIBERTY Phase 3 trials. The company ended the quarter with $160.1 million in cash, which it says funds operations through the DECLARATION pivotal data readout and potential VYD2311 launch readiness. Top-line data from both trials is expected in late Q3 2026. This follows the Nasdaq delisting notice received in July after the stock closed below $1.00 for 30 consecutive days, adding pressure on the company to deliver positive clinical results.
At the time of this announcement, IVVD was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202M. The 52-week trading range was $0.48 to $3.07. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.